The Uromigos

summary
This detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan and Levatnib combination versus Cabozantinib. Brian, Tom and Bob Motzer analyze efficacy, safety, and implications for treatment sequencing.

This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of Belzutifan combined with Pembrolizumab, mechanistic insights, biomarker development, and future research directions.

The conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemoradiotherapy in muscle-invasive bladder cancer. The discussion covers the study's design, patient population, results, and implications for future treatment strategies, emphasizing the importance of patient selection and the potential for TAR-200 in earlier treatment settings.

In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histologies, and the importance of neoadjuvant systemic therapy. The hosts conclude with reflections on future directions in bladder cancer treatment and the significance of ongoing studies.

In this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3 trial, the implications of crossing survival curves, and the evolving role of radioligand therapy and PARP inhibitors in prostate cancer treatment.